{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo&page=77",
    "query": {
      "intervention": "placebo",
      "page": 77
    },
    "page_size": 10
  },
  "pagination": {
    "page": 77,
    "page_size": 10,
    "total_count": 33116,
    "total_pages": 3312,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo&page=78&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo&page=76&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T20:14:02.458Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02993406",
      "title": "Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Statin Adverse Reaction"
      ],
      "interventions": [
        {
          "name": "Bempedoic acid 180 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Esperion Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 13970,
      "start_date": "2016-12-22",
      "completion_date": "2022-11-07",
      "has_results": true,
      "last_update_posted_date": "2024-01-03",
      "last_synced_at": "2026-10-29T20:14:02.458Z",
      "location_count": 304,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 246 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02993406"
    },
    {
      "nct_id": "NCT06334133",
      "title": "Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Cadisegliatin 800 mg QD",
          "type": "DRUG"
        },
        {
          "name": "Cadisegliatin 800 mg BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "vTv Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2024-06-14",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-29T20:14:02.458Z",
      "location_count": 51,
      "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Granada Hills, California + 44 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06334133"
    },
    {
      "nct_id": "NCT01896544",
      "title": "Cholecalciferol Supplementation for Sepsis in the ICU",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypovitaminosis D"
      ],
      "interventions": [
        {
          "name": "Cholecalciferol",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2014-01",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-06-13",
      "last_synced_at": "2026-10-29T20:14:02.458Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01896544"
    },
    {
      "nct_id": "NCT03409614",
      "title": "Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "REGN2810",
          "type": "DRUG"
        },
        {
          "name": "REGN2810/chemo/ipi",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 789,
      "start_date": "2018-03-06",
      "completion_date": "2025-02-27",
      "has_results": true,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-10-29T20:14:02.458Z",
      "location_count": 9,
      "location_summary": "Rancho Mirage, California • Riverside, California • Whittier, California + 6 more",
      "locations": [
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03409614"
    },
    {
      "nct_id": "NCT06020014",
      "title": "Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "AZD4604",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 339,
      "start_date": "2023-11-16",
      "completion_date": "2025-10-28",
      "has_results": false,
      "last_update_posted_date": "2025-11-13",
      "last_synced_at": "2026-10-29T20:14:02.458Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Newport Beach, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06020014"
    },
    {
      "nct_id": "NCT00238316",
      "title": "Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "letrozole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NCIC Clinical Trials Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "Up to 120 Years · Female only"
      },
      "enrollment_count": 68,
      "start_date": "2000-12-05",
      "completion_date": "2009-02-10",
      "has_results": false,
      "last_update_posted_date": "2020-04-02",
      "last_synced_at": "2026-10-29T20:14:02.458Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00238316"
    },
    {
      "nct_id": "NCT02918006",
      "title": "A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "VXA-A1.1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Tablets",
          "type": "OTHER"
        },
        {
          "name": "Saline Solution for Placebo IM Injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Vaxart",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 179,
      "start_date": "2016-08-31",
      "completion_date": "2018-01-19",
      "has_results": true,
      "last_update_posted_date": "2022-10-06",
      "last_synced_at": "2026-10-29T20:14:02.458Z",
      "location_count": 1,
      "location_summary": "Costa Mesa, California",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02918006"
    },
    {
      "nct_id": "NCT03686384",
      "title": "SVT-15652 Otic Solution for the Treatment of Otomycosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Otomycosis"
      ],
      "interventions": [
        {
          "name": "SVT-15652",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Salvat",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 217,
      "start_date": "2020-02-27",
      "completion_date": "2021-10-25",
      "has_results": true,
      "last_update_posted_date": "2024-12-03",
      "last_synced_at": "2026-10-29T20:14:02.458Z",
      "location_count": 1,
      "location_summary": "Orangeburg, South Carolina",
      "locations": [
        {
          "city": "Orangeburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03686384"
    },
    {
      "nct_id": "NCT01746784",
      "title": "Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "N6022",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nivalis Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2014-02",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2014-11-24",
      "last_synced_at": "2026-10-29T20:14:02.458Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Palo Alto, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01746784"
    },
    {
      "nct_id": "NCT04434352",
      "title": "Low Intensity Shockwave Therapy for Erectile Dysfunction",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Erectile Dysfunction",
        "Erectile Dysfunction Following Radical Prostatectomy",
        "Erectile Dysfunction Following Radiation Therapy",
        "Erectile Dysfunction Due to General Medical Condition",
        "Erectile Dysfunction Due to Arterial Insufficiency"
      ],
      "interventions": [
        {
          "name": "Storz Duolith Low-Intensity Shockwave Therapy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "MALE",
        "summary": "30 Years to 80 Years · Male only"
      },
      "enrollment_count": 338,
      "start_date": "2020-06-01",
      "completion_date": "2025-01-09",
      "has_results": false,
      "last_update_posted_date": "2024-05-10",
      "last_synced_at": "2026-10-29T20:14:02.458Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04434352"
    }
  ]
}